Načítá se...
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Poly (ADP‐ribose) polymerase (PARP) inhibitors have provided great clinical benefits to ovarian cancer patients. To date, three PARP inhibitors, namely, olaparib, rucaparib and niraparib have been approved for the treatment of ovarian cancer in the United States. Homologous recombination deficiency...
Uloženo v:
| Vydáno v: | J Cell Mol Med |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6433712/ https://ncbi.nlm.nih.gov/pubmed/30672100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14133 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|